期刊文献+

非小细胞肺癌中TAMs、Ki-67的表达及预后意义 被引量:4

Expression and prognostic significance of TAMs and Ki-67 in non small cell lung cancer
下载PDF
导出
摘要 目的探讨肿瘤相关巨噬细胞(tumor associated macrophages,TAMs)、肿瘤增殖因子(Ki-67)在非小细胞肺癌(non-small cell lung cancer,NSCLC)中的表达及其与临床病理特征的关系,并研究其与预后的关系。方法采用免疫组织化学SP法检测68例NSCLC组织和17例癌旁正常肺组织中CD68(TAMs表面标志)、Ki-67的表达情况。根据随访结果,应用Kaplan-Meier生存分析和Cox回归法分析CD68、Ki-67与肺癌预后的关系。结果CD68、Ki-67在68例肺癌组织中的阳性率分别为66.2%(45/68)、61.8%(42/68),在正常肺组织中的阳性表达率分别为17.6%(3/17)、5.9%(1/17),差异均有统计学意义(P<0.05)。CD68、Ki-67在高TNM分期、淋巴结转移、侵及胸膜的NSCLC组织中的表达明显著增高(P<0.05)。低分化者Ki-67的表达明显增高(P<0.05)。NSCLC中CD68与Ki-67的表达呈正相关(r=0.461,P=0.000)。68例NSCLC患者1、3、5年生存率分别为86.76%、64.71%、16.18%。Cox多因素分析显示,分化程度低和淋巴结转移是预后不良的危险因素(P<0.05)。结论 CD68、Ki-67阳性肺癌患者预后差。CD68、Ki-67在NSCLC的发展、浸润、转移中起一定作用,联合检测可作为临床诊断、辅助治疗的潜在靶点。 Objective To investigate the expression levels of tumor associated macrophages (TAMs),tumor proliferation factor (Ki-67 )in non-small cell lung cancer (NSCLC)and their relationships with the clinical pathological features,and to study its relationship with prognosis. Methods Immunohistochemical SPmethod was used to analyze the expressions of CD68(TAMs surface marker)Ki-67 and in 68 cases of NSCLC tissues and 17 cases of normal lung tissues. According to the results of follow-up,Kaplan-Meier survival analysis and Cox regression analysis of CD68,Ki-67 was used to study its relationship with lung cancer prognosis.Results The positive rates of CD68 and Ki-67 in 68 cases of lung cancer were 66.2%(45/68)and 61.8%(42/68).The positive expression rates of CD68 and Ki-67 in normal lung tissues were 17.6%(3/17), 5.9%(1/17),the difference was statistically significant(P〈0.05).The expression of CD68 and Ki-67 in NSCLC tissues with high TNM stage, lymph node metastasis and invasion were significantly increased (P〈 0.05 ).In addition,the expression of Ki-67 in poorly differentiated patients increased.There was a positive correlation between CD68 and Ki-67 expression in&nbsp;NSCLC(r =0.461,P=0.000).Sixty-eight patients with NSCLC 1,3,5-year survival rate were 86.76%,64.71%,16.18%.Cox multivariate analysis showed that the low degree of differentiation and lymph node metastasis are risky factors for adverse prognosis(P〈0.05).Conclusion CD68,Ki-67-positive lung cancer patients with poor prognosis.CD68 and Ki-67 play a role in the development,invasion and metastasis of NSCLC,and combined detection of them provide a potential target for clinical diagnosis,adjuvant therapy of NSCLC.
出处 《河北医科大学学报》 CAS 2017年第10期1135-1140,共6页 Journal of Hebei Medical University
基金 河北省医学科学研究重点课题计划(ZD20140479)
关键词 非小细胞肺 肿瘤相关巨噬细胞 细胞增殖因子 carcinoma non-small-cell lung tumor associated macrophages Ki-67
  • 相关文献

参考文献11

二级参考文献188

  • 1Chung Hwan Jun,Ho Seok Ki,Hoon Ki Lee,Kang Jin Park,Seon Young Park,Sung Bum Cho,Chang Hwan Park,Young Eun Joo,Hyun Soo Kim,Sung Kyu Choi,Jong Sun Rew.Clinical significance and risk factors of postembolization fever in patients with hepatocellular carcinoma[J].World Journal of Gastroenterology,2013,19(2):284-289. 被引量:7
  • 2陈昊,李玉民,何明彦,李汛,周文策,孟文勃,张磊.胃不典型增生和癌组织中Ki67和PTEN蛋白的表达及意义[J].中国普外基础与临床杂志,2007,14(3):304-307. 被引量:18
  • 3张梅娟,张丽华.免疫标记物D2-40在病理诊断中的应用和意义[J].诊断学理论与实践,2007,6(3):277-280. 被引量:20
  • 4Campo E, Swerdlow SH, Harris NL, et al. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications [ J ]. Blood, 2011,117 ( 19 ) : 5019-5032.
  • 5Li JM, Wang L, Shen Y, et al. Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in Chinese patients [ J ]. Ann Hematol, 2007, 86 ( 9 ) : 639-645.
  • 6Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma[ J 3. N Engl J Med, 2002, 346 (4) : 235 -242.
  • 7Coiffier B, Thieblemont C, Van Deneste E, et al. Long-term outcome of patients in the LNH-98. 5 trial, the firstrandomized study comparing rituximab-CHOP to standard CHOP chemotherapyin DLBCLpafients:astudyby the Groupe d'Etudes des T.vmnhnm,rlo lrAcl,,hol- T3 RIA filN 11g/1")' '3NAN "Ar.
  • 8Habermann TM, Weller EA, Morrison VA, et al. Rituximab- CHOP versus CHOP alone or with maintenancerituximab in older patients with diffuse large B-cell lymphoma [ J ]. J Clin Oncol, 2006, 24(19) :3121-3127.
  • 9Pfreundschuh M, Kuhnt E, Tramper L, et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomisedstudy of theMabThera International Trial (MINT) Group[ J]. Lancet Oncol, 2011, 12( 11 ) : 1013-1022.
  • 10Pfreundschuh M, Schubert J, Ziepert M, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patientswith aggressive CD20 + B-cell lymphomas: a randomised controlled trial (RICOVER-60) [ J ]. Lancet Oncol, 2008, 9(2) :105-116.

共引文献104

同被引文献45

引证文献4

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部